Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

0(0%)

Results Posted

167%(5 trials)

Terminated

2(25%)

Phase Distribution

Ph phase_1

50%

Ph phase_3

13%

Ph phase_2

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

4(50.0%)

Phase 2Efficacy & side effects

3(37.5%)

Phase 3Large-scale testing

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

37.5%

3 of 8 finished

Non-Completion Rate

62.5%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(5)

Detailed Status

Completed3

Withdrawn3

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (50.0%)

Phase 23 (37.5%)

Phase 31 (12.5%)

Trials by Status

completed338%

terminated225%

withdrawn338%

Recent Activity

0 active trials

Showing 5 of 8

terminatedphase_2

Clinical Trials (8)

Showing 8 of 8 trials

NCT03549338Phase 2

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Terminated

NCT02568046Phase 1

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Terminated

NCT03717038Phase 3

Sym004 Versus TAS-102 in Patients With mCRC

Withdrawn

NCT01117428Phase 1

Sym004 in Patients With Advanced Solid Tumors

Completed

NCT01417936Phase 2

Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy

Completed

NCT02924233Phase 1

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Withdrawn

NCT01955473Phase 1

Japanese Phase 1 Trial of Sym004 in Solid Tumors

Completed

NCT02965417Phase 2

Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8